Oral -Lactam Pairs for the Treatment of Mycobacterium avium Complex Pulmonary Disease
The Journal of infectious diseases(2023)
摘要
Cure rates for pulmonary disease caused by the Mycobacterium avium complex (MAC) are poor. While beta-lactam are front line antibiotics against Mycobacterium abscessus pulmonary disease, they have not been used or recommended to treat MAC lung infections. Through a comprehensive screen of oral beta-lactams, we have discovered that selected pairs combining either a penem/carbapenem or penicillin with a cephalosporin are strongly bactericidal at clinically achieved concentrations. These dual beta-lactam combinations include tebipenem and sulopenem, both in phase 3, and Food and Drug Administration-approved amoxicillin and cefuroxime. They could therefore immediately enter clinical trials or clinical practice.
更多查看译文
关键词
nontuberculous mycobacteria,Mycobacterium avium complex,beta-lactam,synergy,target attainment,tebipenem,sulopenem,amoxicillin,cefuroxime
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要